Epidemiology and Outcome of Idiopathic Generalized Epilepsy in Adults.
Drug resistant idiopathic generalized epilepsy (IGE) remains challenging despite a favorable overall prognosis of IGE and little is known about basic epidemiology and long-term outcome of drug resistant IGE. We aimed at describing the incidence, prevalence, and outcome of IGE in an unbiased, population-based cohort. In 2014-2018, all patients (≥17 years) with IGE inhabiting the island of Funen (496,000 inhabitants) were recruited. We assessed socioeconomic and clinical information available for 406 individuals. Median follow-up was 15 years. The average IGE incidence (2008-2017) was 2.9/100,000 inhabitants/year. The point prevalence of identifiable IGE patients was 1.0/1,000 adults (juvenile myoclonic epilepsy: 0.4/1,000; absence epilepsy: 0.3/1,000, epilepsy with generalized tonic-clonic seizures alone: 0.3/1,000), 92.1% of the patients were diagnosed before 25 years of age. When correcting for unequal age distribution in the cohort, 1,102 people on the island of Funen fulfilled the diagnostic criteria for IGE at the age of 25 (estimated prevalence: 2.7/1,000 adults). In the year before data closure, 121 patients reported seizures. Fifty patients met the definition of drug resistant IGE (12.1% of the cohort, 4.5% of the estimated 1,102 IGE patients). The average seizure burden of all patients with drug resistant IGE was 2.2 generalized tonic-clonic seizures/year, only 14 patients suffered more than two generalized tonic-clonic seizures/year. Drug resistant IGE was associated with an increased risk of requiring treatment for affective disorders and a reduced probability of working fulltime. IGE was associated with a low risk of persistent drug resistant seizures requiring specialist medical attention. Drug resistance was associated with a negative socioeconomic outcome.